Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in Melanomas With ALK Alterations
NCT03420508Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2018
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensartinib in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2018; status: active, not recruiting.
02
Drugs
ensartinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03420508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420508.